Skip to main navigation Skip to search Skip to main content

Clinical psychopharmacology of eating disorders : a research update

Research output: Contribution to journalArticlepeer-review

81 Citations (Scopus)

Abstract

The paper presents a critical review (with search date 2010) of the major psychotropic medications assessed in eating disorders, namely antipsychotics, antidepressants, mood-stabilizing medications, anxiolytic and other agents. The evidence of efficacy of drug treatments is mostly weak or moderate. In addition, attrition rates are usually higher than for psychotherapies. However, there is support for use of antidepressants, particularly high-dose fluoxetine in bulimia nervosa, and anticonvulsants (topiramate) for binge-eating disorder. Low-dose antipsychotic medication may be clinically useful as adjunct treatment in acute anorexia, particularly where there is high anxiety and obsessive eating-related ruminations and failure to engage, but more trials are needed. Drug therapies such as topiramate and anti-obesity medication may aid weight loss in obese or overweight patients with binge-eating disorder; however, common or potentially serious adverse effects limit their use.
Original languageEnglish
Pages (from-to)209-222
Number of pages14
JournalInternational Journal of Neuropsychopharmacology
Volume15
Issue number2
DOIs
Publication statusPublished - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • anorexia nervosa
  • antipsychotic agents
  • bulimia
  • compulsive eating
  • eating disorders
  • psychopharmacology

Fingerprint

Dive into the research topics of 'Clinical psychopharmacology of eating disorders : a research update'. Together they form a unique fingerprint.

Cite this